{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:50Z","timestamp":1793640710032,"version":"4.5.1"},"reference-count":16,"publisher":null,"issue":"2","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/cardio.elpub.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/jats:italic>\n                    To evaluate the dynamic impact of an 8-month glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy with semaglutide on anthropometric metrics, blood lipid profiles, and adipokine status in obese patients, with and without type 2 diabetes mellitus (T2DM).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods<\/jats:italic>\n                    \u00a0\u00a0\u00a0 The study included 65 patients with obesity, 26 of whom had T2DM. All participants were prescribed semaglutide, with dose titration up to 1 mg once weekly over 8 months. Before and after the treatment period, the following variables were assessed: anthropometric data (body weight, body weight index, waist circumference), biochemical parameters (lipid profile, glucose, aspartate aminotransferase, alanine aminotransferase, creatinine), and adipokine concentrations (leptin, adiponectin, resistin) via immunofluorescence assay.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    \u00a0 Semaglutide therapy was associated with a statistically significant reduction in body weight (p&lt;0.001), body mass index (p&lt;0.001), and waist circumference (p&lt;0.001). Improvements in the lipid profile were observed over time, including decreased concentrations of low-density lipoprotein cholesterol (p=0.001), triglycerides (p&lt;0.001), and total cholesterol (p=0.001), alongside an increase in high-density lipoprotein cholesterol (p&lt;0.01). Therapy significantly impacted adipokine status: a statistically significant increase in anti-atherogenic adiponectin (p&lt;0.001) and a decrease in leptin levels (p&lt;0.001) were recorded, indicating improved adipose tissue metabolic function. However, no significant changes in resistin concentrations were found. Additionally, positive effects on liver and kidney function markers were noted, manifested by reductions in aspartate aminotransferase and alanine aminotransferase activity, as well as creatinine levels. In the subgroup of patients with T2DM, a statistically significant improvement in glycemic control was observed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Semaglutide therapy for 8 months in obese patients yielded a robust cardiometabolic impact, characterized by significant weight reduction, optimized lipid profiles, and improved liver and kidney function markers, alongside a favorable restructuring of adipokine status. These results support the use of GLP-1 RAs not only for glycemic and weight control but also as a multifaceted cardioprotective therapy for obese patients.\n                  <\/jats:p>\n                  <jats:p>\u00a0<\/jats:p>","DOI":"10.18087\/cardio.2026.2.n3116","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:33:26Z","timestamp":1775129606000},"page":"31-40","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients"],"prefix":"10.68900","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2487","authenticated-orcid":true,"given":"A. V.","family":"Tyurina","sequence":"first","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8126-1330","authenticated-orcid":true,"given":"N. S.","family":"Kurochkina","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1518-6552","authenticated-orcid":true,"given":"M. V.","family":"Yezhov","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221\u201332. DOI: 10.1056\/NEJMoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang C-Z, Wan J-Y et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. DOI: 10.1136\/bmj-2023-076410","DOI":"10.1136\/bmj-2023-076410"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534\u201345. DOI: 10.1001\/jama.2022.0078","DOI":"10.1001\/jama.2022.0078"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ghusn W, De La Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open. 2022;5(9):e2231982. DOI: 10.1001\/jamanetworkopen.2022.31982","DOI":"10.1001\/jamanetworkopen.2022.31982"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250\u201397. DOI: 10.15829\/1560-4071-2023-5471","DOI":"10.15829\/1560-4071-2023-5471"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Szekeres Z, Nagy A, Jahner K, Szabados E. Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism \u2013 A Narrative Review. International Journal of Molecular Sciences. 2024;25(15):8214. DOI: 10.3390\/ijms25158214","DOI":"10.3390\/ijms25158214"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Park MJ, Kim H, Kim MG, Kim K. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis. Clinical and Molecular Hepatology. 2023;29(3):693\u2013704. DOI: 10.3350\/cmh.2022.0330","DOI":"10.3350\/cmh.2022.0330"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pradhan R, Yin H, Yu O, Azoulay L. Glucagon-Like Peptide 1 Receptor Agonists and Sodium\u2013Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. Diabetes Care. 2022;45(4):819\u201329. DOI: 10.2337\/dc21-1953","DOI":"10.2337\/dc21-1953"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024;391(2):109\u201321. DOI: 10.1056\/NEJMoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Simental\u2010Mend\u00eda LE, S\u00e1nchez\u2010Garc\u00eda A, Linden\u2010Torres E, Simental\u2010Mend\u00eda M. Impact of glucagon\u2010like peptide\u20101 receptor agonists on adiponectin concentrations: A meta\u2010analysis of randomized controlled trials. British Journal of Clinical Pharmacology. 2021;87(11):4140\u20139. DOI: 10.1111\/bcp.14855","DOI":"10.1111\/bcp.14855"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Kim Chung LT, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochemical and Biophysical Research Communications. 2009;390(3):613\u20138. DOI: 10.1016\/j.bbrc.2009.10.015","DOI":"10.1016\/j.bbrc.2009.10.015"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Al Refaie A, Baldassini L, Mondillo C, Ceccarelli E, Tarquini R, Gennari L et al. Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study. Endocrine. 2024;87(3):951\u20138. DOI: 10.1007\/s12020-024-04085-8","DOI":"10.1007\/s12020-024-04085-8"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rolland C, Hession, Broom. Effect of weight loss on adipokine levels in obese patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011;4:315\u201323. DOI: 10.2147\/DMSO.S22788","DOI":"10.2147\/DMSO.S22788"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Miklishanskaya S.V., Mazur N.A. Rational approaches to the treatment of patients with overweight and obesity: a cardiologist\u2019s view. Rational Pharmacotherapy in Cardiology. 2024;20(6):652\u20139. DOI: 10.20996\/1819-6446-2024-3087","DOI":"10.20996\/1819-6446-2024-3087"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Martins FF, Santos-Reis T, Marinho TS, Aguila MB, Mandarim-deLacerda CA. Hypothalamic anorexigenic signaling pathways (leptin, amylin, and proopiomelanocortin) are semaglutide (GLP-1 analog) targets in obesity control in mice. Life Sciences. 2023;313:121268. DOI: 10.1016\/j.lfs.2022.121268","DOI":"10.1016\/j.lfs.2022.121268"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Tanyanskiy D.A. Role of adiponectin in atherogenesis: fundamental aspects and perspectives in translation into clinical practice. Complex Issues of Cardiovascular Diseases. 2024;13(1):179\u201395. DOI: 10.17802\/2306-1278-2024-13-1-179-195","DOI":"10.17802\/2306-1278-2024-13-1-179-195"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/viewFile\/3116\/1986","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:51Z","timestamp":1793639811000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/3116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2026.2.n3116","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}